PMID- 24621065 OWN - NLM STAT- MEDLINE DCOM- 20151022 LR - 20150413 IS - 1476-8305 (Electronic) IS - 1028-415X (Linking) VI - 18 IP - 4 DP - 2015 May TI - Zinc monotherapy increases serum brain-derived neurotrophic factor (BDNF) levels and decreases depressive symptoms in overweight or obese subjects: a double-blind, randomized, placebo-controlled trial. PG - 162-8 LID - 10.1179/1476830513Y.0000000105 [doi] AB - OBJECTIVE: Previous studies have shown a positive effect of zinc as an adjunctive therapy on reducing depressive symptoms. However, to our knowledge, no study has examined the effect of zinc monotherapy on mood. The aim of the present study was to determine the effects of zinc monotherapy on depressive symptoms and serum brain-derived neurotrophic factor (BDNF) levels in overweight or obese subjects. METHODS: Fifty overweight or obese subjects were randomly assigned into two groups and received either 30 mg zinc or placebo daily for 12 weeks. At baseline and post-intervention, depression severity was assessed using Beck depression inventory II (BDI II), and serum BDNF and zinc levels were determined by enzyme-linked immunosorbent assay and atomic absorption spectrophotometry, respectively. RESULTS: The trial was completed with 46 subjects. After a 12-week supplementation, serum zinc and BDNF levels increased significantly in the zinc-supplemented group compared with the placebo group. BDI scores declined in both the groups at the end of the study, but reduction in the zinc-supplemented group was significantly higher than the placebo group. More analysis revealed that following supplementation, BDI scores decreased in subgroup of subjects with depressive symptoms (BDI >/= 10) (n = 30), but did not change in the subgroup of non-depressed subjects (BDI < 10) (n = 16). Moreover, a significant inverse correlation was observed between serum BDNF levels and depression severity in all participants. Interestingly, a significant positive correlation was found between serum BDNF and zinc levels at baseline. CONCLUSION: Zinc monotherapy improves mood in overweight or obese subjects most likely through increasing BDNF levels. FAU - Solati, Zahra AU - Solati Z FAU - Jazayeri, Shima AU - Jazayeri S FAU - Tehrani-Doost, Mehdi AU - Tehrani-Doost M FAU - Mahmoodianfard, Salma AU - Mahmoodianfard S FAU - Gohari, Mahmood Reza AU - Gohari MR LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20140107 PL - England TA - Nutr Neurosci JT - Nutritional neuroscience JID - 100892202 RN - 0 (Brain-Derived Neurotrophic Factor) RN - J41CSQ7QDS (Zinc) SB - IM MH - Adult MH - Brain-Derived Neurotrophic Factor/*blood MH - Depression/blood/*diet therapy/psychology MH - *Dietary Supplements MH - Double-Blind Method MH - Female MH - Humans MH - Male MH - Middle Aged MH - Obesity/blood/psychology MH - Overweight/blood/*psychology MH - Psychiatric Status Rating Scales MH - Zinc/administration & dosage/*blood/*pharmacology OTO - NOTNLM OT - Brain-derived neurotrophic factor (BDNF) OT - Depression OT - Obesity OT - Zinc EDAT- 2014/03/14 06:00 MHDA- 2015/10/23 06:00 CRDT- 2014/03/14 06:00 PHST- 2014/03/14 06:00 [entrez] PHST- 2014/03/14 06:00 [pubmed] PHST- 2015/10/23 06:00 [medline] AID - 10.1179/1476830513Y.0000000105 [doi] PST - ppublish SO - Nutr Neurosci. 2015 May;18(4):162-8. doi: 10.1179/1476830513Y.0000000105. Epub 2014 Jan 7.